← Back to contracts

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

US · MD National Institutes of Health (NIH) grant open #PAR-25-069
Response due Jan 07, 2027 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting R01 research grant applications to investigate the biological mechanisms by which incretin mimetics (e.g., GLP-1 receptor agonists and related drugs) may impact cancer risk. Clinical trials are optional under this funding opportunity. The opportunity is open for an extended period, accepting submissions through January 2027, consistent with a standing/reissued NIH Program Announcement with Review (PAR). This is a federal research funding opportunity, not a traditional procurement contract.

What they want

Applicants must propose research investigating the mechanisms through which the use of incretin mimetic drugs (such as GLP-1 receptor agonists) affects cancer risk in humans or relevant model systems. Clinical trial components are optional. Proposals must follow the NIH R01 grant mechanism requirements. The funding opportunity number is PAR-25-069.
Technical requirements
  • Research must address biological/mechanistic basis of cancer risk associated with incretin mimetic drug use
  • Clinical trial component is optional (not required)
  • Must conform to NIH R01 grant mechanism requirements
  • Opportunity number PAR-25-069 must be referenced in application

How they evaluate

  • NIH peer review (scientific merit)
  • Significance
  • Investigator qualifications
  • Innovation
  • Approach
  • Environment
Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

  • Extended open window (over 2 years) is standard for NIH standing PAR announcements, not a red flag per se, but unusual for traditional procurement
  • No dollar value disclosed — award amounts depend on NIH peer review and appropriations
  • Document type is 'synopsis' only — full FOA details not provided in source text, limiting full scope assessment

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541711
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Mechanisms that Impact Cancer Risk with Us…
Due Jan 07
Onboard ↗